Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Patients With Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Brief Summary: Chemotherapy given together is a standard way to treat your cancer. One standard treatment includes a combination of docetaxel, cisplatin, and fluorouracil. However, the original combination of these three drugs can cause many side effects. This study is being done to find out if these three drugs can be given at lower doses more often, with fewer side effects and still maintain the same benefit as the standard way of giving this three drug combination. If your tumor overexpresses a protein called Her2, you are also eligible to receive trastuzumab with chemotherapy. Trastuzumab is a medicine that has been approved by the US Food and Drug Administration for the treatment of Her2 positive breast cancer. Trastuzumab is now also a standard treatment in combination with chemotherapy for the treatment of Her2 positive stomach cancer. If your tumor is Her2 positive, you would receive the modified administration schedule of docetaxel, cisplatin, and fluorouracil with trastuzumab.


Options:
A: Arm Label: Everolimus + BSC; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Best Supportive Care (BSC) | Arm Label: Placebo + BSC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Everolimus placebo, Drug: Best Supportive Care (BSC) | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus + BSC | Intervention Type: DRUG; Name: Everolimus placebo; Assigned to Arm(s): Placebo + BSC | Intervention Type: DRUG; Name: Best Supportive Care (BSC); Assigned to Arm(s): Everolimus + BSC, Placebo + BSC
B: Arm Label: Sunitinib; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Arm A, - Modified DCF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Leucovorin, Fluorouracil, Cisplatin | Arm Label: ARM B - Parent DCF with G-CSF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen | Arm Label: Arm C - Modifid DCF + Trastuzumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab | Intervention Type: DRUG; Name: Docetaxel, Leucovorin, Fluorouracil, Cisplatin; Assigned to Arm(s): Arm A, - Modified DCF | Intervention Type: DRUG; Name: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen; Assigned to Arm(s): ARM B - Parent DCF with G-CSF | Intervention Type: DRUG; Name: Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab; Assigned to Arm(s): Arm C - Modifid DCF + Trastuzumab
D: Arm Label: TE (Taxotere and Eloxatin); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin | Arm Label: TEF (Taxotere, Eloxatin and 5-FU); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + 5-FU | Arm Label: TEX (Taxotere, Eloxatin and Xeloda); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + Capecitabine | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin; Assigned to Arm(s): TE (Taxotere and Eloxatin) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + 5-FU; Assigned to Arm(s): TEF (Taxotere, Eloxatin and 5-FU) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + Capecitabine; Assigned to Arm(s): TEX (Taxotere, Eloxatin and Xeloda)

Answer: C